Loading…
← CockpitCompetitor Analysis › 2005.HK SSY Group LimitedOpen in the cockpit ↗

SSY Group Limited2005.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major

Chinese manufacturer of large-volume intravenous infusion solutions and generic injectable drugs for hospitals.

≈ A Chinese Baxter International-style IV-fluids and generic-injectables makerMomentum leader 82
Mkt cap
$948M
US dollars, full cap
Free float
33%
of shares outstanding
$/day
$1.20M
20-day average traded
Fwd P/E
12.5×
forward earnings
ROIC−WACC
-2.0 pp
WACC 6.2%
Hurdle
+3 pp
Req g minus delivered
Next earnings
128 days
26 Mar 2027
Close · HKDHK$2.52
1D-0.6%
1W-4.2%
1M-6.2%
3M+5.0%
6M+7.7%
YTD-10.9%
1Y-20.0%
ATR %2.8%
52w lowhigh20.8% off high

What SSY does

Chinese manufacturer of large-volume intravenous infusion solutions and generic injectable drugs for hospitals.

Sells IV solutions and injectables in bulk to hospitals, largely through distributors, with prices set in government-run provincial bidding rounds, so winning tenders matters more than branding.

In one line: A Chinese Baxter International-style IV-fluids and generic-injectables maker.

Products and services

  • IV infusion solutions
  • Generic injectable drugs
  • Antibiotic formulations

Customers

  • Hospitals across China

Where it sits in the supply chain

  • Pharmaceuticals
  • Generic injectable drugs
  • Large-volume parenteral (IV) solutions

What could go right

  • Hospital demand growth in China

What could go wrong

  • Centralized procurement price cuts on commodity IV products

Moat: narrow (scale, regulatory licence, distribution). Large manufacturing scale and hospital distribution network for commodity IV products.

Headquarters: Guangzhou, China · Founded: 1988 · Employees: 5,500

Named competitors

SSY at a glance

Size SSY (2005.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $948M, the 595th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$2.52 on 18 Nov 2026.

Performance Over six months the shares gained 7.7%, against -20.3% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 4th highest of 21 in its peer set.

Growth Revenue fell 4.4% over the last twelve months (peer median +2.4%); the operating margin is 12.2% (peer median 8.8%).

Valuation It trades at 12.5× forward earnings against a peer median of 24.5× (2nd cheapest of 10).

Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.0 points below its cost of capital (6.2% WACC).

Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 20262005.HK 109Peer median 82
Six months, rebased to 100: SSY against the median of its 20 peers (local-currency closes).

SSY financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$4.38BHK$4.17BHK$5.77BHK$6.46BHK$6.43B
Revenue growth—-28%-11%0%—
Gross profitHK$1.70BHK$1.62BHK$2.81BHK$3.49BHK$3.44B
EBITDAHK$985MHK$886MHK$1.68BHK$1.93BHK$1.73B
Net incomeHK$507MHK$471MHK$1.06BHK$1.32BHK$1.12B
Free cash flowHK$898MHK$559MHK$221MHK$437MHK$584M
Capital expenditureHK$228MHK$241MHK$540MHK$704MHK$418M
Total debtn/aHK$4.01BHK$3.64BHK$3.37BHK$3.21B

Quarterly statements and history in the cockpit →

SSY competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%+20%STAR60353800243760042230029468875968817703920045651795MLTXPGHLSPTX688382AARTIPHARM25952005.HK6-month return →1-month return →
Up and to the right = strong over both horizons. SSY is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%20×40×60×STAR603538300294039200456517956001292005.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. SSY is the large dot.

Capital: growth delivered against growth the price implies

-50%-25%0%+25%-50%0%STAR60353800243760025203920045653004011795PGHL6883822005.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. SSY is the large dot.

SSY competitors and peer comparison

Head to head with its named competitors (2005.HK vs 002422.SZ vs 1513.HK vs BAX)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
SSY 2005.HK$948M+8%-4%12%12.5×2.3%
Sichuan Kelun Pharmaceutical 002422.SZ$10.1B+35%0%9%35.6×6.2%
Livzon Pharmaceutical 1513.HK$3.73B-9%-10%19%11.3×-7.0%
Baxter International BAX$13.5B+39%+5%6%12.7×13.4%

How SSY compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

SSY against its 20 peers (data as of 18 Nov 2026)
Measure2005.HKPeer medianRank in peer set
1-month return-6.2%-9.1%8th highest of 21
6-month return+7.7%-20.3%4th highest of 21
Distance from 52-week high-20.8%-46.9%3rd highest of 21
Revenue growth (TTM)-4.4%+2.4%9th lowest of 18
Operating margin12.2%8.8%9th highest of 18
Forward P/E12.5×24.5×2nd cheapest of 10
Growth the price implies (Req g, 7 yrs)2.3%8.4%3rd least demanding of 11
Growth delivered (Del g)-0.5%+8.5%4th lowest of 11
Hurdle (Req g minus delivered)+2.8 pp+1.5 pp6th least demanding of 11
ROIC minus cost of capital-2.0 pp-2.0 pp8th highest of 16
EV / EBITDA10.0×15.9×2nd cheapest of 7
Net debt / EBITDA2.1×1.8×3rd most indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
SSY 2005.HKHong Kong$948M+8%-4%12%12.5×2.3%-0.5%
Strides Pharma Science STAR.NSIndia$946M-17%+11%14%15.9×17.6%+7.8%
Ningbo Menovo Pharmaceutical 603538.SSChina$945M-48%+19%9%42.3×11.6%+4.9%
Harbin Gloria Pharmaceuticals 002437.SZChina$941M-9%-16%13%n/a7.7%-6.9%
KPC Pharmaceuticals 600422.SSChina$940M-6%-41%-10%n/an/an/a
China Resources Boya Bio-pharmaceutical 300294.SZChina$959M-21%-27%-19%21.4×n/an/a
BeBetter Med 688759.SSChina$960M-58%n/an/an/an/an/a
Guangxi Wuzhou Zhongheng 600252.SSChina$936M-10%-43%-42%n/a10.3%-13.7%
Bio-Thera Solutions 688177.SSChina$929M-23%+24%-44%n/an/an/a
Oscotec 039200.KSSouth Korea$923M-32%+510%59%50.2×-10.2%+18.1%
Nxera Pharma 4565.TJapan$974M+46%+24%14%25.8×17.7%+27.3%
Zhejiang Garden Biopharmaceutical 300401.SZChina$922M-14%+2%24%22.9×9.1%+13.4%
Lotus Pharmaceutical 1795.TWTaiwan$921M-37%+67%21%9.8×-3.7%+13.8%
MoonLake Immunotherapeutics MLTXUnited States$918M-37%n/an/an/an/an/a
Procter & Gamble Health PGHL.NSIndia$979M+3%+13%31%24.5×5.6%+9.3%
Seaport Therapeutics SPTXUnited States$980M+16%n/an/an/an/an/a
Chongqing Taiji Industry (Group) 600129.SSChina$982M-20%-4%2%69.8×n/an/a
InventisBio 688382.SSChina$982M-47%-61%-563%n/a6.5%-60.6%
Aarti Pharmalabs AARTIPHARM.NSIndia$984M+44%+13%18%n/an/an/a
Immatics IMTXUnited States$913M-46%-44%-589%n/an/an/a
Genfleet Therapeutics (Shanghai) 2595.HKHong Kong$912M-42%-55%-457%n/an/an/a

Questions

Who are SSY's main competitors?
Named competitors: Kelun Pharmaceutical (002422.SZ), Livzon Pharmaceutical (1513.HK), Baxter International (BAX). The cockpit's measured peer set (industry) also includes Strides Pharma Science (STAR.NS), Ningbo Menovo Pharmaceutical (603538.SS), Harbin Gloria Pharmaceuticals (002437.SZ), KPC Pharmaceuticals (600422.SS), China Resources Boya Bio-pharmaceutical (300294.SZ), BeBetter Med (688759.SS).
Is SSY expensive compared with its peers?
On forward p/e it trades at 12.5× against a peer median of 24.5×, 2nd cheapest of 10 in its peer set. For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has SSY stock performed?
Over six months to 18 Nov 2026 the shares returned +7.7% against -20.3% for the median peer; over one year -20.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.